The Sarcoma Alliance for Research through Collaboration (SARC) in partnership with the National Cancer Institute (NCI) is currently recruiting patients for its Phase II trial (SARC-022) of Linsitinib (OSI-906), an IGF-1R inhibitor.

Linsitinib is targeted at patients with either Pediatric or Adult Wildtype GIST, and participants in the trial must have a confirmation of one of these mutations to participate in the trial. The trial is currently ongoing both at Dana-Farber Cancer Institute in Boston and Fox Chase Cancer Center in Philadelphia.


The principal investigator for the trial is Dr. Margaret von Mehren at Fox Chase.  SARC has stated that they plan to open seven to eight additional sites throughout the country, including the University of Michigan, Oregon Health & Science University, and the National Cancer Institute.

For more information on the trial, please contact SARC at 734-930-7600, or access the trial’s page on (, where additional information about eligibility requirements and trial objectives can also be found.

Pete Knox
Author: Pete Knox